Schedule 13G Filing by Perceptive Advisors LLC for Tenax Therapeutics, Inc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed a Schedule 13G, reporting beneficial ownership of 439,142 shares of Tenax Therapeutics, Inc. common stock. This represents 7.0% of the outstanding shares as of November 11, 2025. Perceptive Advisors acts as the investment manager for the Master Fund, and Mr. Edelman is the managing member of Perceptive Advisors. The filing indicates that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The filing date was December 23, 2025, with an event date of December 18, 2025.